Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
876 stopped studies mapped to Malignant Male Reproductive System Neoplasm and descendants · 91% state a reason
Over the 876 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03284346 | Exercise in Targeting Metabolic Dysregulation in Stage I-III Breast or Prostate Cancer… | N/A | terminated | Sep 15, 2017 | University of Southern California | PI left | Investigator |
| NCT06527690 | Race Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients…(REPRESENTATION) | Phase 2 | withdrawn | Jul 30, 2024 | Latin American Cooperative Oncology Group | The study aimed to include multiple countries in Latin America, but only Brazil was feasible,… | Enrollment / accrual |
| NCT06516510 | A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide… | Early Phase 1 | terminated | Jul 24, 2024 | Blue Earth Therapeutics Ltd | Based on data from the Interim Analysis, the study will not adequately inform the clinical… | Safety / toxicity |
| NCT04996849 | Contemporary Characteristics of Penile Cancer | — | terminated | Aug 9, 2021 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT06528210 | Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of… | Phase 2 | withdrawn | Jul 30, 2024 | OHSU Knight Cancer Institute | Loss of funding | Funding |
| NCT05445609 | Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic… | Phase 2 | suspended | Jul 6, 2022 | Emory University | Per sponsor memo screening and enrollment of new patients for all ongoing Regeneron sponsored… | Enrollment / accrual |
| NCT02869282 | Circulating And Intra-Tumoral Chemokines In Patients With Prostate Cancer(CHEMOPROST) | — | withdrawn | Aug 16, 2016 | Institut Bergonié | Principal investigator left the study center and nobody took over the study. | Investigator |
| NCT05733351 | Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With… | Phase 1 | terminated | Feb 17, 2023 | Emory University | To review the safety data. | Safety / toxicity |
| NCT05820633 | Pelvic Nodes Ultra-Hypo vs Conventionally Fractionated IMRT With HDR Boost in Prostate…(PCS-XI) | N/A | suspended | Apr 19, 2023 | CHU de Quebec-Universite Laval | amendment to be done, adding 200 patients | Other (stated, no rule matched) |
| NCT04580667 | Determination of Assay Cut-Off for the RadTox Test in Prostate Cancer Patients to Predict… | — | withdrawn | Oct 8, 2020 | DiaCarta, Inc. | The sponsor declared bankruptcy | Other (stated, no rule matched) |
| NCT03485794 | Collection of Blood in Studying Metabolites in Patients With Prostate Cancer | — | terminated | Apr 2, 2018 | University of Southern California | Insufficient Accrual | Enrollment / accrual |
| NCT04336943 | Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a… | Phase 2 | terminated | Apr 7, 2020 | University of Washington | Slow accrual | Enrollment / accrual |
| NCT05369000 | Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant… | Phase 1 | terminated | May 11, 2022 | Lava Therapeutics | The trial was intended to be a Phase 1/2 trial (but the trial never moved forward to Phase 2). | Other (stated, no rule matched) |
| NCT04832997 | Micro-ultrasound for Prostate Cancer Diagnosis | N/A | terminated | Apr 6, 2021 | IRCCS San Raffaele | The study faced structural and methodological obstacles, with limited enrollment, technical issues,… | Enrollment / accrual |
| NCT06655064 | Registry to Evaluate Long-Term Outcomes in Patients Who Undergo 68-Ga-PSMA-11 PET/CT… | — | terminated | Oct 23, 2024 | Telix Pharmaceuticals (Innovations) Pty Limited | Sponsor request | Other (stated, no rule matched) |
| NCT03432897 | BrUOG 337: Olaparib Prior to Radical Prostatectomy For Advanced Prostate Cancer Defects…(337) | Phase 2 | terminated | Feb 14, 2018 | Brown University | Lack of enrollment secondary to eligibility criteria | Enrollment / accrual |
| NCT04569461 | Trimodality Approach of Low Dose iOnizing Radiation With or Without Neoadjuvant…(TALON) | Phase 2 | withdrawn | Sep 29, 2020 | Duke University | Discontinuation of funding | Funding |
| NCT03815942 | VAccination in Early and ADvanced Prostate caNCEr(ADVANCE) | Phase 1 / Phase 2 | terminated | Jan 24, 2019 | University of Oxford | COVID stopped all trials - and ADVANCE could not restart again after the pandemic | COVID-19 / pandemic |
| NCT05333432 | Evaluation of a Multimodal Strategy for Early Diagnosis of Men at High Genetic Risk of…(HRPCa-II) | N/A | withdrawn | Apr 19, 2022 | Assistance Publique - Hôpitaux de Paris | difficulties in setting up the study within the investigation centers in connection with complex… | Other (stated, no rule matched) |
| NCT04102124 | A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC | Phase 2 | terminated | Sep 25, 2019 | Jiangsu HengRui Medicine Co., Ltd. | The sponsor's R\&D strategy is adjusted. | Sponsor / business decision |
| NCT01231932 | Characterizing Fatigue Experienced by Cancer Patients Receiving Primary Treatment and… | — | terminated | Nov 1, 2010 | National Institute of Nursing Research (NINR) | Principal Investigator (PI) of this study is retiring. | Investigator |
| NCT04740034 | A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma | Phase 1 | terminated | Feb 5, 2021 | Amgen | Sponsor strategic decision | Sponsor / business decision |
| NCT05712174 | A Study of [18]F-PSMA-1007 in Patients With Known or Suspected Metastatic Prostate Cancer | Phase 2 | terminated | Feb 3, 2023 | AHS Cancer Control Alberta | Accrual to the biochemically recurrent and metastatic cohorts complete; however, accrual to the… | Enrollment / accrual |
| NCT03712371 | Study of Chitosan for Pharmacologic Manipulation of AGE Levels in Prostate Cancer Patients | Phase 1 / Phase 2 | terminated | Oct 19, 2018 | Medical University of South Carolina | Interim study results were not favorable to continue with further enrollment. | Enrollment / accrual |
| NCT01673984 | GP Extended Action Triptorelin(GREAT) | Phase 4 | terminated | Aug 28, 2012 | Ipsen | The study was discontinued prematurely by the sponsor due to non-medical reasons | Other (stated, no rule matched) |
| NCT04927663 | 11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression | Phase 1 | terminated | Jun 16, 2021 | Rahul Aggarwal | Slow accrual | Enrollment / accrual |
| NCT00635167 | Contrast Enhanced Transrectal Ultrasonography (TRUS) to Assess Prostatic Vascularity… | N/A | terminated | Mar 13, 2008 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Closed by PI final report submitted | Other (stated, no rule matched) |
| NCT04926181 | Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine… | Phase 2 | terminated | Jun 15, 2021 | Rahul Aggarwal | Funding | Funding |
| NCT03300505 | ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer | Phase 1 | terminated | Oct 3, 2017 | University of Michigan Rogel Cancer Center | Cancelled by the sponsor | Other (stated, no rule matched) |
| NCT05177770 | Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With… | Phase 2 | terminated | Jan 5, 2022 | Coherus Oncology, Inc. | The study was terminated for strategic reasons, not due to any safety concerns. | Safety / toxicity |
| NCT04607135 | ARFI Imaging for Targeted Prostate Biopsy | N/A | terminated | Oct 29, 2020 | Duke University | Current sample size sufficiently powers the study to evaluate outcome measures | Other (stated, no rule matched) |
| NCT01341288 | Robotic Seed Implantation for Prostate Cancer Brachytherapy(EUCLIDIAN) | Phase 1 | terminated | Apr 25, 2011 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Slow accrual | Enrollment / accrual |
| NCT01313559 | Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone… | Phase 2 | terminated | Mar 11, 2011 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Slow accrual | Enrollment / accrual |
| NCT03076242 | Genetic Evaluation of Men (GEM) | — | terminated | Mar 10, 2017 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Competing trial | Other (stated, no rule matched) |
| NCT03477864 | Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in… | Phase 1 | withdrawn | Mar 26, 2018 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Study was not accruing | Enrollment / accrual |
| NCT05819827 | Associations Between Chemotherapy-Induced Nausea in Patients With Genitourinary, Sarcoma… | — | terminated | Apr 19, 2023 | Mayo Clinic | Low/slow accrual | Enrollment / accrual |
| NCT06795178 | Efficacy, Safety, and Pharmacokinetics of FP-014, 11.25 mg in Patients With Advanced…(KATANA E3M) | Phase 3 | withdrawn | Jan 27, 2025 | Foresee Pharmaceuticals Co., Ltd. | Business reasons not safety related. | Safety / toxicity |
| NCT06795191 | Efficacy, Safety, and Pharmacokinetics of FP-014, 22.5 mg in Patients With Advanced…(KATANA E6M) | Phase 3 | withdrawn | Jan 27, 2025 | Foresee Pharmaceuticals Co., Ltd. | Business reasons not safety related. | Safety / toxicity |
| NCT03581500 | Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in… | Phase 2 | withdrawn | Jul 10, 2018 | M.D. Anderson Cancer Center | Committee could not find that the regulatory approval are met to re-approve this study. | Other (stated, no rule matched) |
| NCT03764540 | Docetaxel Versus Cabazitaxel Post Abiraterone or Enzalutamide(CABPOSTAAT) | Phase 2 | terminated | Dec 5, 2018 | Centre hospitalier de l'Université de Montréal (CHUM) | The cabazitaxel was recently approved by the regulatory authorities for mCRPCa | Other (stated, no rule matched) |
| NCT05815316 | 18F-PSMA PET/MRI for the Diagnosis of Clinically Significant Prostate Cancer | Phase 2 | withdrawn | Apr 18, 2023 | IRCCS San Raffaele | error in the registration on clincialtrials.gov. The same clinical trial has been correctly… | Other (stated, no rule matched) |
| NCT04556617 | PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With… | Phase 1 / Phase 2 | terminated | Sep 21, 2020 | Opna Bio LLC | study terminated due to business realignment | Sponsor / business decision |
| NCT04383210 | Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid… | Phase 2 | terminated | May 12, 2020 | Elevation Oncology | Business decision | Sponsor / business decision |
| NCT06375629 | ES-HIFU, Prospective Data Collection of Patients Treated With Partial Gland HIFU Ablation…(ES-HIFU) | — | terminated | Apr 19, 2024 | EDAP TMS S.A. | The study was terminated early to integrate sites into a larger registry for a more comprehensive… | Safety / toxicity |
| NCT05208229 | The Role of WB-MRI in the Evaluation of Prostate Cancer Patients Treated With Lutetium -…(WB-LuPSMA) | — | terminated | Jan 26, 2022 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | The study was linked to another protocol that is over | Other (stated, no rule matched) |
| NCT06094842 | Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen… | Phase 1 | withdrawn | Oct 23, 2023 | Fred Hutchinson Cancer Center | Study closed before opening to accrual | Enrollment / accrual |
| NCT04382898 | PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)(PRO-MERIT) | Phase 1 / Phase 2 | terminated | May 11, 2020 | BioNTech SE | Sponsor decision | Sponsor / business decision |
| NCT04298983 | Abemaciclib in Combination With Androgen Deprivation Therapy for Locally Advanced…(RAD 1805) | Phase 2 | terminated | Mar 6, 2020 | University of Alabama at Birmingham | Abemaciclib efficacy | Efficacy / futility |
| NCT06257758 | A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors | Phase 1 / Phase 2 | terminated | Feb 14, 2024 | Valerio Therapeutics | Business decision | Sponsor / business decision |
| NCT06643494 | Elimination of Prostate Cancer Treatment Side Effects Using a Nutraceutical | Phase 1 / Phase 2 | suspended | Oct 16, 2024 | Optimal Health Research | PPI currently unable to continue. | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Sep 29, 2025source: clinicaltrials